Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen

Executive Summary

Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.

Related Content

Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says
Roche Pegasys/Copegus Monitoring For Severe Infections Advised By Cmte.
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
PEG-Intron/Rebetol Subgroups Should Be Analyzed, Cmte. Says
Schering PEG-Intron/Rebetol committee update
Schering Rebetol Costs $1,650 Per Month, 3% Less Than Combo Rebetron
Schering PEG-Intron Phase IV Trial To Study African Americans



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts